Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | APEX1 | P27695 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.44 |
| ▸ | TUBB | P07437 | 1/20 | 0.44 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3780939 | 0.89 | KDM4E (0.72) | KDM4EATMTAAR1TSHRMAPK1 | |
| SCHEMBL15760679 | 0.89 | TUBB4A (0.53) | KDM4EATMTAAR1TSHRMAPK1 | |
| SCHEMBL17637575 | 0.87 | TUBB4A (0.51) | KDM4EATMTAAR1TSHRMAPK1 | |
| SCHEMBL2468726 | 0.85 | ATM (0.79) | KDM4EATMTAAR1TSHRMAPK1 | |
| SCHEMBL16900310 | 0.84 | TUBB4A (0.49) | KDM4EATMTAAR1TSHRMAPK1 | |
| SCHEMBL12020315 | 0.84 | SKP2 (0.53) | KDM4EATMMAPK1CYP1A2CYP3A4 | |
| SCHEMBL23112136 | 0.82 | KDM4E (0.58) | KDM4EATMTAAR1TSHRMAPK1 | |
| SCHEMBL19248448 | 0.82 | KDM4E (0.58) | KDM4EATMTAAR1TSHRMAPK1 | |
| SCHEMBL23239959 | 0.82 | CYP2C8 (0.47) | KDM4EATMTAAR1TSHRMAPK1 | |
| SCHEMBL6173908 | 0.82 | TNKS2 (0.57) | KDM4EATMTAAR1TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504420-B2 | Compounds which inhibit beta-secretase activity and methods of use | COMENTIS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20080176939-A1 | COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | COMENTIS, INC. (US) | 2008-07-24 | — | — | US | disclosed |
| EP-1871739-A1 | COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | COMENTIS, INC. (US) | 2008-01-02 | — | — | EP | disclosed |
| US-20070117793-A1 | Compounds Which Inhibit Beta-Secretase Activity and Methods of Use | ZAPAQ, INC. (US) | 2007-05-24 | — | — | US | disclosed |
| WO-2006110668-A1 | COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | COMENTIS, INC. (US) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117793-A1 | Compounds Which Inhibit Beta-Secretase Activity and Methods of Use | BACE1, BACE2, APP | KDM4E 2484/4885ATM 3727/4885TAAR1 4588/4885 |
| US-20080176939-A1 | COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | BACE1, BACE2, APP | KDM4E 2768/4885ATM 3871/4885TAAR1 4597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.